key: cord-0860994-sk6qv0fz
authors: Amit, Sharon; Beni, Sharon Alexsandra; Biber, Asaf; Grinberg, Amir; Leshem, Eyal; Regev-Yochay, Gili
title: Postvaccination COVID-19 among Healthcare Workers, Israel
date: 2021-04-03
journal: Emerg Infect Dis
DOI: 10.3201/eid2704.210016
sha: 9f86fe4ea92c243e76b4aeed84084d7f5c196913
doc_id: 860994
cord_uid: sk6qv0fz

Coronavirus disease (COVID-19) symptoms can be mistaken for vaccine-related side effects during initial days after immunization. Among 4,081 vaccinated healthcare workers in Israel, 22 (0.54%) developed COVID-19 from 1–10 days (median 3.5 days) after immunization. Clinicians should not dismiss postvaccination symptoms as vaccine-related and should promptly test for COVID-19.

L arge-scale vaccination of risk groups and later the general population is the single most effective public health measure for mitigation of the coronavirus disease (COVID-19) pandemic. National COVID-19 vaccination programs started during December 2020 in several countries and prioritized healthcare workers (HCWs) (1) . In some countries the vaccination programs coincided with a surge in detected COVID-19 cases and increased burden on the healthcare system (2).

During December 2020-January 2021, Israel experienced a surge in COVID-19 incidence that resulted in the third national lockdown imposed since the pandemic began in early 2020 (3) . Concomitantly, during December 2020, Israel's Ministry of Health approved the Pfi zer-BioNTech COVID-19 vaccine (BNT162b2; Pfi zer Inc., https://www.pfi zer.com) and prioritized HCWs for immunization (4) .

Sheba Medical Center is a large hospital with 9,069 staff members in Ramat-Gan, Israel. The hospital started its personnel vaccination program on December 20, 2020, and excluded workers who had recovered from COVID-19. During the fi rst week of the campaign, 4,081 (45%) eligible staff members received the fi rst dose of BNT162b2. Concurrently, the national COVID-19 positivity rate rapidly increased to >6% on January 3, 2021 (2).

The hospital's Infection Prevention and Control Unit conducted active and passive surveillance of vaccinated staff by using daily health questionnaires, hotlines, on-call infectious disease unit staff, and post-vacci-nation web-based questionnaires to identify and test symptomatic HCWs. Among 4,081 HCWs vaccinated in the fi rst week of the campaign, 22 (0.54%) later had laboratory-confi rmed COVID-19 (Table) . The average age among COVID-19-positive vaccinated HCWs was 45.3 years (±9.85 years), and they belonged to different healthcare sectors and worked on various wards.

Among the 22 vaccinated HCWs who tested positive for COVID-19, 13 were tested because they had symptoms, most commonly an infl uenza-like illness that included fever, chills, cough, headache, myalgia, and sore throat. Two vaccinated HCWs were tested because of exposure to confi rmed or suspected COV-ID-19 cases yet reported symptoms upon questioning. Asymptomatic COVID-19 cases were identifi ed among HCWs as part of postexposure screening. Among the 22 COVID-19-positive HCWs, 11 had presumable community-related exposures, 4 of whom reported exposure incidents that occurred before or on the date of vaccination. An investigation conducted by the hospital's Infection Control and Prevention Unit identifi ed 10 healthcare-related secondary exposures. However, we did not identify any point-source exposures or CO-VID-19 clusters linked to the immunization process.

Among the 11 vaccinated HCWs who reported COVID-19 symptoms, the median time between the fi rst dose of BNT162b2 immunization and symptom onset was 3.5 (range 0-10) days; we excluded 1 vaccinee from our calculation and analysis because the HCW had symptoms before immunization (Table) . The median time between the onset of symptoms and testing was 1 day, demonstrating the high level of suspicion for COVID-19 during the vaccination campaign.

Of note, apart from the need for early detection, persons who test positive for COVID-19 after receiving the fi rst vaccine dose (whether asymptomatic and tested following exposure or tested because they are symptomatic) are not eligible to receive the second dose, according to Ministry of Health policy. However, depending on availability of vaccines, this policy might change when further data are collected. 

COVID-19 in HCWs is a major concern for health authorities worldwide. HCWs, especially acute and chronic care facility personnel, are at high risk for contracting symptomatic and asymptomatic COVID-19 and might become infected at home or nosocomially while caring for patients or interacting with other staff members (5) (6) (7) . Infections among HCWs have an immediate effect on their close occupational environment and the overall healthcare system. Secondary exposures, isolation, and infections of staff can substantially impair the capacity of a single ward to care for patients, creating a snowball effect with collateral damage to both the functional resilience of the facility and morale of staff. Consequently, as soon as COVID-19 vaccines were deployed in Israel, HCWs were the first group to receive it.

We report 22 cases of early, postimmunization, laboratory-confirmed COVID-19 among HCWs during the launch of the vaccination campaign in a large hospital in Israel. BNT162b2 is not likely to exert protection against clinical disease during the first days after receipt of the first dose. Efficacy of the BNT162b was 52% a week after the first dose, and positive CO-VID-19 cases were described among vaccinees even early after the second dose (8) . Thus, during a largescale immunization campaign coinciding with rapid national increase in COVID-19 cases, some immunized persons likely will develop clinical disease.

The co-occurrence of vaccination deployment with the rapidly climbing COVID-19 spread in many parts of the world is a confusing period in which hope is mixed with great vulnerability. The phenomenon of pandemic fatigue, in which the population tires of constant safety precautions, testing, isolation, and restrictions, could lead to less social distancing and personal protection. Pandemic fatigue coupled with the availability of a vaccine, might give the population a false sense of reassurance and consequently lead to a brisk increase in COVID-19 cases. Thus, almost every physical complaint after vaccination poses a true diagnostic dilemma as to whether an adverse reaction or a new COVID-19 infection is the cause. Undetected COVID-19 cases among HCWs could be hazardous for patients and other staff. Clinicians should have a high level of suspicion of reported symptoms and avoid dismissing complaints as vaccine-related until true infection is ruled out and vaccinees are tested. Active and passive surveillance that enables rapid testing and initiation of infection control measures are essential in preventing possible diagnostic delays and secondary exposures. Therefore, healthcare-related indications for testing should not be altered until systematic and exhaustive data are gathered regarding vaccine effectiveness in healthcare settings.

Dr. Amit is a certified internist, infectious disease specialist, and clinical microbiologist, and is the director of the Clinical Microbiology Laboratory Department at Sheba Medical Center, Israel. Her fields of research include clinical microbiology and communicable diseases epidemiology.

Having standard biological reference materials, such as antigens and antibodies, is crucial for developing comparable research across international institutions. However, the process of developing a standard can be long and difficult.

In this EID podcast, Dr. Tommy Rampling, a clinician and academic fellow at the Hospital for Tropical Diseases and University College in London, explains the intricacies behind the development and distribution of biological reference materials.

The Advisory Committee on Immunization Practices' interim recommendation for allocating initial supplies of COVID-19 vaccine-United States

Buying time with COVID-19 outbreak response

State of Israel Ministry of Health. Coronavirus (COVID-19) vaccines

Risk for SARS-CoV-2 infection in healthcare workers

High proportion of asymptomatic SARS-CoV-2 infections in 9 long-term care facilities

SARS-CoV-2 seroprevalence among healthcare, first response, and public safety personnel

C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine